Administration of heat shock protein 65 inhibits murine melanoma growth in vivo

Yang,Jie; Xie,Yanfei; Wang,Huaqian; Yao,Yi; Hou,Jing; Ma,Yanjun; Zhang,Qing; Xing,Yun; Wu, Jie; Li,Taiming; Zheng,Junnian; Liu,Jingjing; Cao,Rongyue

doi:10.3892/mmr.2012.1167

Administration of heat shock protein 65 inhibits murine melanoma growth in vivo

Authors:
- Jie Yang
- Yanfei Xie
- Huaqian Wang
- Yi Yao
- Jing Hou
- Yanjun Ma
- Qing Zhang
- Yun Xing
- Jie Wu
- Taiming Li
- Junnian Zheng
- Jingjing Liu
- Rongyue Cao
View Affiliations

Affiliations: Minigene Pharmacy Laboratory, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, P.R. China, Jiangsu Key Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Xuzhou 221002, P.R. China
Published online on: November 6, 2012 https://doi.org/10.3892/mmr.2012.1167
Pages: 171-176

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The association between heat shock protein (HSP) 65 and immune diseases has been investigated for many years. The aim of this study was to explore the antitumor effects and possible antitumor mechanism of HSP65. Mice were immunized with HSP65 via subcutaneous injection. Specific IgG antibodies against HSP65 were detected in the sera of immunized mice by enzyme‑linked immunosorbent assay and verified by western blot analysis. HSP65 effectively inhibited the growth of tumors as well as both the protective and therapeutic antitumor immunities in the melanoma tumor models of mice and prolonged the survival of the tumor-bearing mice. Furthermore, HSP65 also attenuated tumor-induced angiogenesis in the intradermal model and pulmonary metastasis in the tail intravenously injected model of mice. It was demonstrated that the administration of HSP65 is able to effectively inhibit the growth, angiogenesis and metastasis of murine melanoma in vivo and provide new prospects for the immunotherapy of melanoma.

View Figures

View References

1	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2	Emmett MS, Dewing D and Pritchard-Jones RO: Angiogenesis and melanoma - from basic science to clinical trials. Am J Cancer Res. 1:852–868. 2011.PubMed/NCBI
3	Carlson JA, Slominski A, Linette GP, et al: Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging. Am J Clin Pathol. 120(Suppl): S101–S127. 2003.PubMed/NCBI
4	Eggermont AM: Advances in systemic treatment of melanoma. Ann Oncol. 21(Suppl 7): vii339–344. 2010. View Article : Google Scholar : PubMed/NCBI
5	Griguer CE, Oliva CR, Kelley EE, Giles GI, Lancaster JR Jr and Gillespie GY: Xanthine oxidase-dependent regulation of hypoxia-inducible factor in cancer cells. Cancer Res. 66:2257–2263. 2006. View Article : Google Scholar : PubMed/NCBI
6	Schmitt E, Gehrmann M, Brunet M, Multhoff G and Garrido C: Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol. 81:15–27. 2007. View Article : Google Scholar : PubMed/NCBI
7	Graner MW, Cumming RI and Bigner DD: The heat shock response and chaperones/heat shock proteins in brain tumors: surface expression, release, and possible immune consequences. J Neurosci. 27:11214–11227. 2007. View Article : Google Scholar : PubMed/NCBI
8	Eustace BK and Jay DG: Extracellular roles for the molecular chaperone, hsp90. Cell Cycle. 3:1098–1100. 2004. View Article : Google Scholar : PubMed/NCBI
9	Xu X, Wang W, Shao W, et al: Heat shock protein-60 expression was significantly correlated with the prognosis of lung adenocarcinoma. J Surg Oncol. 104:598–603. 2011. View Article : Google Scholar : PubMed/NCBI
10	Lin C-S, He P-J, Tsai N-M, et al: A potential role for Helicobacter pylori heat shock protein 60 in gastric tumorigenesis. Biochem Biophys Res Commun. 392:183–189. 2010.
11	Hwang YJ, Lee SP, Kim SY, et al: Expression of heat shock protein 60 kDa is upregulated in cervical cancer. Yonsei Med J. 50:399–406. 2009. View Article : Google Scholar : PubMed/NCBI
12	Cappello F, David S, Rappa F, et al: The expression of HSP60 and HSP10 in large bowel carcinomas with lymph node metastase. BMC Cancer. 5:1392005. View Article : Google Scholar : PubMed/NCBI
13	Kamal A, Boehm MF and Burrows FJ: Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol Med. 10:283–290. 2004. View Article : Google Scholar : PubMed/NCBI
14	Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A and Kroemer G: HSP27 and HSP70: potentially oncogenic apoptosis inhibitors. Cell Cycle. 2:579–584. 2003. View Article : Google Scholar : PubMed/NCBI
15	Sedlackova L, Spacek M, Holler E, Imryskova Z and Hromadnikova I: Heat-shock protein expression in leukemia. Tumour Biol. 32:33–44. 2010. View Article : Google Scholar
16	Xiong Q, Jin L, Li J, et al: A Th2 immune shift to heat shock protein 65 fails to arrest atherosclerosis: proatherogenic role of Th2-deviated autoantibodies. Autoimmunity. 42:475–483. 2009. View Article : Google Scholar : PubMed/NCBI
17	Ausiello CM, Fedele G, Palazzo R, Spensieri F, Ciervo A and Cassone A: 60-kDa heat shock protein of Chlamydia pneumoniae promotes a T helper type 1 immune response through IL-12/IL-23 production in monocyte-derived dendritic cells. Microbes Infect. 8:714–720. 2006.PubMed/NCBI
18	Chen K, Lu J, Wang L and Gan YH: Mycobacterial heat shock protein 65 enhances antigen cross-presentation in dendritic cells independent of Toll-like receptor 4 signaling. J Leukoc Biol. 75:260–266. 2004. View Article : Google Scholar : PubMed/NCBI
19	Zhao Y, Yokota K, Ayada K, et al: Helicobacter pylori heat-shock protein 60 induces interleukin-8 via a Toll-like receptor (TLR)2 and mitogen-activated protein (MAP) kinase pathway in human monocytes. J Med Microbiol. 56:154–164. 2007. View Article : Google Scholar
20	Jin L, Wang Y, Xiong Q, et al: Long-lasting specific antibodies against P277 induced by mucosal administration of P277 repeat sequences carried by Hsp65 in the absence of adjuvants. Vaccine. 25:2043–2050. 2007. View Article : Google Scholar : PubMed/NCBI
21	Lu Y, Ouyang K, Fang J, et al: Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope. Vaccine. 27:5411–5418. 2009. View Article : Google Scholar : PubMed/NCBI
22	Guojun W, Wei G, Kedong O, et al: A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo. Endocr Relat Cancer. 15:149–159. 2008. View Article : Google Scholar : PubMed/NCBI
23	Kreisle RA and Ershler WB: Investigation of tumor angiogenesis in an id mouse model: role of host-tumor interactions. J Natl Cancer Inst. 80:849–854. 1988. View Article : Google Scholar : PubMed/NCBI
24	Xiong Q, Li J, Jin L, Liu J and Li T: Nasal immunization with heat shock protein 65 attenuates atherosclerosis and reduces serum lipids in cholesterol-fed wild-type rabbits probably through different mechanisms. Immunol Lett. 125:40–45. 2009. View Article : Google Scholar
25	Marcatili A, Cipollaro de l’Ero G, Galdiero M, Folgore A and Petrillo G: TNF-alpha, IL-1 alpha, IL-6 and ICAM-1 expression in human keratinocytes stimulated in vitro with Escherichia coli heat-shock proteins. Microbiology. 143(Pt 1): 45–53. 1997. View Article : Google Scholar : PubMed/NCBI
26	Lillicrap MS, Duggleby RC, Goodall JC and Gaston JS: T cell recognition of a highly conserved epitope in heat shock protein 60: self-tolerance maintained by TCR distinguishing between asparagine and aspartic acid. Int Immunol. 16:405–414. 2004. View Article : Google Scholar : PubMed/NCBI
27	Hartl FU and Hayer-Hartl M: Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 295:1852–1858. 2002. View Article : Google Scholar : PubMed/NCBI
28	Verdegaal ME, Zegveld ST and van Furth R: Heat shock protein 65 induces CD62e, CD106, and CD54 on cultured human endothelial cells and increases their adhesiveness for monocytes and granulocytes. J Immunol. 157:369–376. 1996.PubMed/NCBI
29	Chin L, Garraway LA and Fisher DE: Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev. 20:2149–2182. 2006. View Article : Google Scholar : PubMed/NCBI
30	Ferrara N: Role of myeloid cells in vascular endothelial growth factor-independent tumor angiogenesis. Curr Opin Hematol. 17:219–224. 2010.PubMed/NCBI
31	Shojaei F, Zhong C, Wu X, Yu L and Ferrara N: Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol. 18:372–378. 2008. View Article : Google Scholar : PubMed/NCBI
32	Yang L, Chen G, Mohanty S, et al: GPR56 regulates VEGF production and angiogenesis during melanoma progression. Cancer Res. 71:5558–5568. 2011. View Article : Google Scholar : PubMed/NCBI
33	Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6. 1990. View Article : Google Scholar : PubMed/NCBI
34	Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
35	Sekulic A, Haluska P Jr, Miller AJ, et al: Malignant melanoma in the 21st century: the emerging molecular landscape. Mayo Clin Proc. 83:825–846. 2008. View Article : Google Scholar : PubMed/NCBI
36	Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology. 69(Suppl 3): 4–10. 2005. View Article : Google Scholar : PubMed/NCBI
37	Verheul HM, Hammers H, van Erp K, et al: Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res. 13:4201–4208. 2007. View Article : Google Scholar
38	Pugh CW and Ratcliffe PJ: Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 9:677–684. 2003. View Article : Google Scholar : PubMed/NCBI